DAASH - Ongoing and enrolling

This is a pilot study to investigate the effectiveness of HCV treatment with velpatasvir/sofosbuvir administered by psychiatrist/licensed buprenorphine/naloxone providers during regularly scheduled visits to an outpatient addiction clinic for buprenorphine/naloxone replacement therapy and mental healthcare, as measured by percentage of patients achieving SVR-12 (defined as HCV RNA < lower limit of quantification (LLOQ) 12 weeks after discontinuation of study treatment.)

For more information, please contact: Community Research Initiative of New England Research Team, 617.502.1707 or

If you would like updates about new, enrolling trials, please fill out the contact form below. Your information will be kept strictly confidential by our research staff.